USANA Health Sciences Sees FY23 EPS $2.65-$3.30 Vs $3.02 Est
Portfolio Pulse from Benzinga Newsdesk
USANA Health Sciences has updated its fiscal 2023 net sales and diluted EPS guidance. The new net sales estimate is $900 to $950 million, up from $875 million to $950 million. The EPS guidance has also been revised to $2.65 to $3.30, from $2.40 to $3.30.
July 25, 2023 | 8:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
USANA Health Sciences has revised its FY23 net sales and EPS guidance upwards. This could potentially lead to a positive market reaction.
USANA Health Sciences has increased its FY23 net sales and EPS guidance. This indicates that the company expects better performance than previously anticipated, which could lead to a positive market reaction. However, the actual impact will depend on various factors, including market conditions and investor sentiment.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100